Acute myeloid leukemia (AML) is a hematologic malignancy characterized by abnormal proliferation and impaired differentiation of myeloid hematopoietic stem cells.[1] In recent years, more and more rare fusion genes have been discovered.[2,3] Based on the distribution of cytogenetically and molecularly defined subsets of AML presenting in adults in WHO 5th classification, the rare fusions accounted for 1% of all subtypes, including t(16;21)(p11;q22)/FUS::ERG. Here, FUS is linked to acute myeloid leukemia.